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Abstract
 
Type 1 diabetes mellitus results from the progressive and specific autoimmune destruction of insulin-secreting pancreatic
B-cells, which develops over a period of years and continues after the initial clinical presentation. The ultimate goal of
therapeutic intervention is prevention or reversal of the disease by the arrest of autoimmunity and by preservation/resto-
ration of B-cell mass and function. Recent clinical trials of antigen-specific or non-specific immune therapies have proved
that modulation of islet specific autoimmunity in humans and prevention of insulin secretion loss in the short term after
the onset of disease is achievable. The identification of suitable candidates for therapy, appropriate dosage and timing,
specificity of intervention and the side-effect profile are crucial for the success of any approach. Considering the complex-
ity of the disease, it is likely that a rationally designed approach of combined immune-based therapies that target suppres-
sion of B-cell specific autoreactivity and maintenance of immune tolerance, coupled with islet regeneration or replacement
of the destroyed B-cell mass, will prove to be most effective in causing remission/reversal of disease in a durable fashion.
Diabet. Med. 25, 1259–1267 (2008)
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Pancreatic B-cell destruction, residual B-cell 
function and timing of intervention
 
During the last decades of the 20th century, there was an
increase in the incidence of Type 1 diabetes mellitus (T1D) in
most regions of the world. Various environmental factors have
been suggested to contribute to this increasing trend (Table 1)
[1–4]. Complex interactions between genetic susceptibility and
environment, influencing the immunological compartment
during the prodromal period, lead in some individuals to overt
immunological abnormalities, including occurrence of auto-
antibodies and islet-reactive T cells [5,6]. Progression of the
disease requires activation of the pathogenic T cells and/or
a decline in immunoregulation followed by an aggressive
attack directed against pancreatic B-cells [6]. Over time, there
is a progressive decrease in B-cell mass mirrored by loss of
insulin secretion and later by overt hyperglycaemia [7,8].
The Diabetes Control and Complications Trial (DCCT)
established support for the relationship between residual B-cell
function and glucose control as individuals who had stimulated
C-peptide levels >  0.2  pmol/ml had improved responses to
treatment and outcomes [9–12]. Thus, preservation of even
some endogenous insulin-producing capacity could have
a significant impact on the long-term disease outcome by
improving glycaemic control. The onset of hyperglycaemia
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is usually followed by transient partial remission, but the
disease continues to develop even after the initial clinical
presentation until there is complete insulinopaenia [7,13].
Therefore, early interventions that preclude the onset of the
disease (before irreversible destruction of B-cell mass occurs)
would be ideal, provided that they are safe and have long-
lasting effects.
The problem with insulin replacement therapy is that it is
not curative, as it does not address directly the cause of the
disease. The goal of any therapeutic intervention is abrogation
of pathogenic reactivity to autoantigens, while preserving full
capacity to mount a normal immune response against foreign
pathogens, with preservation/restoration of B-cell mass and
function. Although a great number of potential therapeutic
candidates have been investigated in preclinical models of
T1D, many of which showed encouraging results, the success-
ful extrapolation of these findings to humans has proven to be
a significantly more difficult task. This is partially because of
the huge complexity and inter-individual heterogeneity in
the pathogenesis of the human disease, illustrated by the
association between younger age at onset and clinical course
(shorter duration of symptoms, more severe metabolic
decompensation at diagnosis and a more rapid rate of progression)
as well as genetic and environmental determinants of the intensity
of the B-cell destructive process (greater genetic susceptibility,
more intense immune response to B-cell antigens) [14–17].
Therefore, designing therapies that would be effective in all
clinical settings is challenging.
Theoretically, therapeutic approaches can be contemplated
at different stages of the natural history of the disease. Current
dilemmas are optimum time of intervention and proper selection
of the candidate population from the perspective of risk/benefit
ratio. Low-risk therapies with minimal side effects can be
administered ethically before clinical onset (in primary prevention
trials), but they require a large number of screened subjects in
order to identify a reasonable number of eligible participants,
are very expensive and may take a long period of time to
document results. In addition, many of the individuals who are
genetically predisposed and even have circulating autoantibodies
do not develop diabetes or it may occur many years later [7].
Unfortunately, it remains difficult to predict who may benefit
from any given intervention, as sufficiently validated and
specific surrogate markers of disease prediction or intervention are
relatively scarce. It is therefore easiest to perform intervention
trials in patients that have been newly diagnosed with T1D as
they already carry a straightforward marker of the disease
(hyperglycaemia), are certainly highly motivated and the disease
course is still amenable to modulation [18]. In addition, these
trials require a smaller number of subjects over shorter periods
of time to demonstrate the effectiveness of intervention.
However, the downside of these interventions is that B-cell
damage is already substantial, making potential treatments
less effective in arresting the autoimmune process. Thus, the
optimal therapeutic approach is the one that ensures a state
of equipoise between risk and benefit, balancing the side
effects/efficacy ratio.
 
Therapeutic strategies for T1D
 
In this article we will review potential therapeutic strategies for
prevention or reversal of T1D in humans with a special emphasis
on those that have reached clinical relevance (are either
approved for therapeutic use or are being tested in clinical
trials of T1D). These approaches broadly address the prevention
of (further) B-cell loss by the arrest of the autoimmune process
and B-cell protection on one hand and B-cell regeneration and
replacement on the other (Table 2). Certainly, the distinction
is only scholastic since there is an extensive overlap between
these areas and presumably a successful intervention requires
a combined approach.
 
Prevention of pancreatic B-cell loss
 
As mentioned, the strategies for prevention of B-cell loss focus
on halting the immune response against B-cells in the pancreatic
islets and also on protection of B-cells by making them more
resistant to the attack. These immunotherapeutic approaches
involve both antigen-specific and non-antigen-specific approaches
which target various components of the pathological cascade
(Fig. 1).
 
Antigen-specific immunotherapy
 
As T1D results from the failure to maintain tolerance to auto-
antigens, targeting them through antigen-specific therapies
should provide effective means of controlling the autoimmune
process by inducing tolerance and also avoid the unwanted
side effects associated with non-specific immunosuppression.
The rationale behind administration of autoantigen in a toler-
ogenic regimen is induction of protective immunity by genera-
tion of antigen-specific regulatory T cells (Tregs), which act by
releasing inhibitory cytokines [e.g. interleukin (IL)-10, IL-4],
by induction of anergy/deletion of autoreactive effector T cells
and possibly by deviation of their phenotype towards a non-
pathogenic one [19–21]. The antigens used as tolerogens have
included insulin, glutamic acid decarboxylase (GAD), heat
Table 1 The most important environmental factors which possibly 
contribute to the increased incidence of Type 1 diabetes [1–4]
Environmental factors Hypothesis
Viral infections 
(e.g. enteroviruses) 
Viral hypothesis
Exposure to certain food 
constituents (gluten; toxic 
agents such as nitrite/nitrate)
Dietary hypothesis
Increased hygiene; lack of 
childhood infections
Hygiene hypothesis
Rapid growth in early 
childhood
Accelerator hypothesis
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Table 2
 
New therapeutic interventions for Type 1 diabetes in humans
Aim of intervention Type of intervention Pros/advantages Cons/disadvantages
Prevention 
of B-cell loss
Immune-based 
therapy
Antigen specific
Insulin, HSP60, 
GAD65 (and their peptides)
Safe
Induction imunoregulatory mechanisms
Moderate clinical benefit (preservation 
of C-peptide over a limited time period) 
in intervention trials
No/partial success in prevention trials so far
Non-antigen specific
Immunosuppresants Induce depletion/inactivation 
of pathogenic cells
Limited/no effect; short- and 
long-term side effects
Nicotinamide Safe No efficacy for diabetes prevention 
Protection against B-cell death
Anti-CD3 mAb Induction of tolerance by apoptosis/
anergy of activated T cells and 
expansion of Tregs
Side effects (moderate cytokine 
release syndrome; transient reactivation 
of EBV; potential anti-idiotypic antibodies)
No chronic immunosuppression
Prevention of loss of insulin production 
> 1 year in intervention trials
Reoccurrence of B-cell failure
Regeneration/restoration 
of B-cell mass
Transplantation Pancreas/islet cells Feasible
Improved glycaemic control
Preferable in simultaneous renal graft 
(when immunosuppression 
is already necessary)
Modest success of the procedure; continuous 
immunosuppression is needed
Islet isolation procedure—technically 
challenging; costly; lack of sufficient 
pancreata (multiple donors per recipient)
Whole pancreas—more invasive surgery
Pharmacologic agents (e.g. GLP-1 receptor agonists, 
DPP-4 inhibitors)
Approved for Type 2 diabetes therapy
Eliminate need for surgical procedures
Presumably stimulates B-cell 
regeneration
Definite effect of B-cell regeneration 
not yet fully evaluated
Long-term safety needs further evaluation
Stem cells/genetic therapy Good potential source of 
surrogate insulin producing cells
Still in preclinical research phase
DPP-4, dipeptidyl peptidase 4; EBV, Epstein–Barr virus; GLP-1, glucagon-like peptide 1; mAb, monoclonal antibody; Tregs, regulatory T cells; HSP, heat shock protein; GAD, glutamic acid decaboxylase.
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shock protein (HSP) and their constituent peptides. They
have been administered by the subcutaneous, oral or nasal
routes and have been tested both in prevention and intervention
trials.
The initial success of the studies in animal models of diabetes
and of a pilot trial in relatives of patients with T1D (which
demonstrated that insulin given before disease onset prevents
or delays diabetes) led to the initiation of a large-scale clinical
trial of an antigen-based therapy for the prevention of diabetes
[22–24]. The Diabetes Prevention Trial—Type  1 (DPT-1)
recruited high-risk relatives of patients with T1D. Participants
were randomly assigned to observation or intervention with
oral or parenteral insulin on the basis of their risk of disease
[25,26]. Parenteral insulin failed to protect against the disease
onset. Overall, oral insulin did not prevent diabetes in all
subjects recruited for that arm of the trial; however, a subsequent
analysis indicated a delay in diabetes onset in the subgroup of
individuals who had high titres of anti-insulin autoantibodies.
Possible explanations for the overall study failure are dosage
(which were empirically calculated based on animal data and
appeared to be 5–8 times lower than the weekly equivalent
dose in mice), schedule of insulin administration, changes in
the protocol and also timing of the intervention or other poorly
defined aspects of the autoimmune response [27–29]. Although
the protection was not complete and not all treated subjects
benefited, this initial partial success raised hopes for future
studies meant to enhance the treatment effect. Type 1 Diabetes
TrialNet (http://www.diabetestrialnet.org) has already initiated
further studies to explore the potential role of oral insulin in
delaying or preventing T1D in relatives whose risk for diabetes
is similar to those in the DPT-1 subgroup. An initial report in
subjects at risk for T1D found that intranasal delivery of
insulin is safe and induced immune changes consistent with
mucosal tolerance to insulin [30]. Additional trials are currently
ongoing [such as the Finnish Diabetes Prediction and Prevention
Project (DIPP)] or planned [Primary Oral/intranasal INsulin
FIGURE 1 Potential therapeutic strategies for prevention/reversal of Type 1 diabetes. These could be contemplated in different stages during the natural 
history of diabetes: in individuals with high genetic risk; for prevention of autoimmunity, in antibody-positive individuals; for prevention of disease 
onset (primary prevention) or after clinical onset; for preservation of residual pancreatic B-cell mass and function (secondary and tertiary prevention). 
Ideally, immune-based therapies should be administered before onset of Type 1 diabetes (or shortly afterwards), when there is still some residual B-cell 
mass that could be rescued. Methods of B-cell replacement are used when there is insufficient B-cell mass that could assure sufficient endogenous insulin 
levels necessary for maintenance of good glycaemic control.
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Trial (Pre-POINT)] and aim to determine the efficacy of nasal
insulin as well as the optimum insulin dose [31,32].
Other studies have used short-term antigen-specific inter-
ventions designed to alter the immune response in a manner
that might result in sustained beneficial effects. An immuno-
modulatory humanized peptide from HSP60 (p277 peptide)
modified to increase its stability 
 
in vivo
 
 (DiaPep277®), has
provided evidence suggestive of better preservation of C-
peptide in recent-onset T1D [33]. At the end of the 10 months
of follow-up, the intervention group had improved mean C-
peptide levels and required significantly less exogenous insulin
to obtain the same level of glycated haemoglobin (HbA
 
1c
 
) as
the control group. Interestingly, drug treatment affected the
phenotype of the response to DiaPep277® in the immunized
subjects, with enhancement of Th2 type cytokine production.
Nevertheless, C-peptide levels decreased later in the treated
group, although the change was less pronounced than in the
placebo group. A similar study carried out in children with
T1D had no beneficial effect in preserving B-cell function or
improving glycaemic control [34–36]. Likewise, the report of
a clinical trial in latent autoimmune diabetes in adults (LADA)
patients using an alum-formulated recombinant human
GAD65 showed promise, as it increased C-peptide levels and
the purported Tregs subset in peripheral blood. The efficacy of
this compound is being examined further in TrialNet intervention
trials [37].
 
Non-antigen-specific immunotherapy
 
Because T1D is a heterogenous disease, and as the initial anti-
genic repertoire as primary target of the immune attack is still
not very well defined, considerable efforts have been devoted
to non-antigenic immune interventions. Initial trials used
broad-spectrum immunosuppressive agents that would deplete
or inactivate pathogenic T  cells. Cyclosporin, azathioprine,
prednisone and anti-thymocytic globulin led to a decrease in
insulin requirements and enhanced endogenous B-cell function
in patients with recent onset of T1D, but the magnitude and
duration of benefits were limited and concern over short- and
long-term toxicity limited their use [38–43].
A large multicentre trial carried out in Europe, the European
Nicotinamide Diabetes Intervention Trial (ENDIT), employing
a similar screening strategy to DPT-1, randomized subjects at
risk to observation or treatment with nicotinamide [44].
Nicotinamide had been shown to modify the course of diabetes
in preclinical models, presumably by direct reduction of cytokine-
mediated B-cell damage [45]. As in DPT-1, the screening
approach was very successful in identifying individuals at risk,
but nicotinamide was not effective in prevention of diabetes in
this cohort.
Noteworthy and promising outcomes have been seen in two
studies using two different humanized anti-CD3 monoclonal
antibodies (anti-CD3) in new-onset T1D. The two anti-CD3
molecules were modified in an attempt to decrease toxicity,
which was seen mainly in the form of cytokine release syndrome
[46,47]. Although the exact mechanisms responsible for the
actions of the anti-CD3 are still not fully elucidated, several
possibilities exist: induction of antigenic modulation, anergy,
induction of apoptosis in activated cells and immune tolerance
through adaptive Tregs [48,49]. Both phase II trials using the
two different anti-CD3 preparations have reported preservation
of B-cell function, with maintenance of higher endogenous
insulin secretion assessed by C-peptide response and concom-
itant reduction in HbA
 
1c
 
 and insulin usage in the treated group
over at least a 1-year period of time [50–52]. In both trials,
adverse events associated with treatment included those of
cytokine release (fever, headache, gastrointestinal symptoms,
rash) that were self-limiting or responsive to symptomatic
therapy. In addition, transient reactivation of the Epstein–Barr
virus (EBV) with signs and symptoms of mononucleosis and
occurrence of anti-idiotype antibodies have been reported
[50–52]. It should be noted that, in spite of the overall initial
efficacy in prevention of disease progression, the effects of the
therapy varied between individuals (with some patients failing
to recover endogenous C-peptide secretion from the beginning
of the treatment) and eventually the decline of insulin produc-
tion was inevitable.
At present, additional studies are being conducted with vari-
ous other non-antigen-specific immunosuppressive/immuno-
modulatory agents and are in different enrolment phases [e.g.
mycophenolate mofetil 
 
±
 
 anti-IL-2 receptor monoclonal antibodies
(daclizumab), anti-CD20 monoclonal antibodies, thymoglobulin,
IL-2 + sirolimus, CTLA4-Ig, IL-1-receptor antagonist] [28].
There has been dramatic progress in the field of immune
interventions designed to interfere with T1D progression, but
unfortunately a single effective immunotherapy has not been
identified so far, although some have shown encouraging
results. Antigen-specific immunotherapies have proved to be
highly specific in modulating B-cell autoimmunity, mainly by
inducing regulatory responses, while non-antigen-specific
interventions mediate protection by clonal deletion/anergy in
activated (pathogenic) T cells, with subsequent differentiation
and expansion of Tregs. For both approaches, identification of
suitable candidates for therapy, appropriate dosage and timing
and specificity of intervention are critical for successful
intervention. Nevertheless, considering the complexity of the
disease, it is most likely that a combination of immune-based
approaches would be most effective in hindering autoimmunity
and maintaining immune tolerance by synergistic effects of
therapies that may allow a reduction of individual dosages and
thus of side effects.
 
Restoration of pancreatic B-cell mass
 
The clinical significance of any interventional therapy for T1D
relies on its ability to maintain, or even increase pancreatic B-
cell mass and function up to the point of insulin independence.
Because at the time of clinical diagnosis a significant proportion
of the B-cell mass has been destroyed (although there may be
less than has been appreciated because of the dysfunctional
islets), restoration of B-cell mass should be attempted along
 
dme(01)_2556.fm  Page 1263  Tuesday, October 28, 2008  8:47 AM 
DIABETIC
 
Medicine Pancreatic B-cell function in Type 1 diabetes • 
 
S. Cernea and P. Pozzilli
 
© 2008 The Authors.
 
1264
 
Journal compilation © 2008 Diabetes UK. 
 
Diabetic Medicine
 
,
 
 
 
25
 
, 1259–1267
 
with methods of immune tolerance; this can be accomplished
by B-cell regeneration or substitution.
 
B-cell regeneration
 
It has been suggested that, in the absence of the autoimmune
process that causes cell death, B-cell regeneration is achievable
mostly by releasing B-cells from glucose toxicity and oxidative
stress and by using regeneration-compatible drugs, that is by
substitution of steroids and cyclosporine (and probably also
sirolimus and tacrolimus) with agents that seem unlikely to
interfere with B-cell proliferation (such as anti-CD3, anti-CD20)
[53–55]. The DCCT showed that intensive insulin therapy helps
sustain endogenous insulin secretion (with stimulated C-peptide
levels above the clinically relevant value of 0.2 pmol/ml),
suggesting that continuous insulin administration and its
glucose-lowering effect is potentially beneficial for B-cell
preservation [56]. There are now compelling data to indicate
that B-cell mass is dynamic and can expand and contract to meet
metabolic demands (e.g. in pregnancy, obesity) but is not clear,
however, whether similar islet mass expansion will occur
following the arrest of autoimmunity by effective treatment of
T1D [57]. In fact, data suggest that following immune therapy
there is a slightly enhanced rate of B-cell apoptosis that con-
tinues afterwards. This most likely reflects a process already set
in motion at diagnosis and which results in progressive decline
in B-cell area [58]. This indicates that immune intervention
alone is not sufficient for effective B-cell restoration. Stimulation
with pharmacological agents or growth factors (such as hepato-
cyte growth factor or insulin-like growth factors) may be used
to achieve B-cell regeneration and many compounds have been
investigated for their ability to induce B-cell replication and
neogenesis and to limit B-cell apoptosis [59,60]. Therapeutic
molecules capable of increasing B-cell mass 
 
in vivo
 
 by systemic
use have the advantage of eliminating the need for invasive
surgical procedures. In animal models, expansion of islet mass
and stimulation of insulin secretion has been shown to occur
in response to glucagon-like peptide 1 (GLP-1) and its receptor
agonists, exendin 4 [61–63]. In addition, in islet transplant
recipients, exendin 4 has stimulated insulin secretion and
demonstrated an ability to reduce exogenous insulin requirements.
Currently, clinical trials are testing the hypothesis that use of
GLP-1 at the time of islet transplantation might be of help in
preserving islet mass [64,65]. Exendin  4 and inhibitors of
dipeptidyl peptidase 4 (DPP-4 inhibits GLP-1 breakdown) are
new drugs already approved for use as adjuvant therapy in
Type 2 diabetes. However, their long-term safety, the durability
of effects and their ultimate role in the management of Type 2
diabetes all require further assessment [66]. However, the
extent of adult B-cell regenerative capacity is not clear and
deeper insight into the effect of these molecules (and other
compounds with potential benefit for islet mass regeneration)
on human B-cell biology is essential before considering their
use for therapeutic purposes in T1D.
It is still a matter of debate whether B-cell renewal occurs by
self-duplication of pre-existing endocrine cells, transdifferentiation
of exocrine cells and/or by proliferation of ductules/adult stem
cells with subsequent differentiation into new islet insulin-
secreting cells [59,60]. While basic research provides some
evidence for both hypotheses, markers for the clear identification
of islet cells that generate insulin-secreting progeny remain
elusive. It is doubtful that spontaneous transdifferentiation of
exocrine cells and/or proliferation of adult stem/progenitor
cells occur in humans and, even if they do occur, the extent of
these processes are not clinically relevant.
 
B-cell replacement
 
B-cell replacement by transplantation of whole organ pancreas
or islet cells are currently regarded as acceptable therapeutic
options for patients with T1D and both have shown benefits in
terms of achieving and maintaining good glycaemic control
[67]. Whole pancreas transplant can be performed in conjunction
with renal transplant in patients with imminent or end-stage
renal disease or as a solitary graft, mainly in diabetic patients
with frequent severe hypoglycaemia or extreme blood glucose
lability, despite optimization of diabetes management [68].
Islet cells transplantation has similar clinical indications and is
a more recent, highly specialized procedure involving implanta-
tion of islet cell preparations into the recipient’s liver sinusoids
via the portal vein, under sonographic and fluoroscopic guidance
[65,68]. In general, islet cell transplantation is a less invasive
procedure but it requires multiple donor organs per recipient
in order to transplant an adequate number of islets. This
represents a major impediment to widespread application
because of the shortage of donor organs [68]. In addition, both
transplantation methods require an immunosuppressive
regimen in order to avoid graft rejection and this limits the
success of the procedures. The Edmonton protocol (currently
accepted as important guidelines for islet cell transplantation)
uses a cyclosporin- and steroid-free immunosuppressive
regimen; however, even in these circumstances, the reported
5-year insulin independent rate is less than 10% [69]. But it
should be noted that C-peptide secretion was maintained in
80% of the patients up to 5 years post-islet transplantation
and that the hypoglycaemic score, lability index and HbA
 
1c
 
improved significantly in those who retained detectable
C-peptide. A trial carried out in several centres of excellence
to explore the feasibility of islet transplantation using the
Edmonton protocol had indicated that only 44% of the recipi-
ents met the primary endpoint, defined as insulin independence
with adequate glycaemic control 1 year after the final trans-
plantation and only 31% of patients remained insulin
independent at 2 years [70]. Nevertheless, the obvious benefits
justify the ongoing efforts to overcome current challenges through
research; mainly development of predictive islet potency tests,
increase of islet availability, improvement of post-transplant
monitoring, enhancement of islet engraftment and, most
importantly, further development of less B-cell toxic immuno-
suppression regimens [65].
Limitation of pancreatic B-cells availability for replacement
has turned the attention of researchers towards finding
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alternative sources of insulin-producing cells. Various strategies
are being investigated and genetic engineering of non-pancreatic
cells, or transforming stem cells into glucose-sensitive insulin-
producing cells, possibly in combination with other treatments,
has generated enthusiasm. We have briefly mentioned before
some of the sources of islet cell surrogates. There is an increasing
body of evidence showing that, in addition to embryonic stem
cells, several potential adult cells derived from pancreas, liver,
spleen or bone marrow can differentiate into insulin-secreting
cells; these cells display some subsets of native B-cell attributes,
but are not yet true functional B-cells [59,60,70]. Thus, the
main challenge is development of methods for differentiation
to completely functional B-cells, which necessitates a deeper
understanding of basic stem cell biology and of stem/progenitor
cell differentiation pathways. Apart from certain ethical issues,
the use of embryonic stem cells raises the risk of tumour
formation as a major concern [60]. However, the use of adult
cells poses other constraints, mainly that they are usually
isolated in small numbers and in general have limited proliferation
capacity [60]. In both cases, yields are still less than adequate
to satisfy clinical needs. In spite of all difficulties and current
limitations, there is evidence that regeneration of B-cells is possible,
yet generation of large number of functional glucose-sensing
insulin-secreting B-cells suitable for therapies may not be feasible
in the immediate future.
 
Conclusions
 
The ultimate goal of any therapeutic intervention is to prevent
or reverse T1D by abrogation of pathogenic autoreactivity and
by preservation or restoration of the B-cell mass and function
to physiologically sufficient levels to maintain stable glucose
control. Recent trials using antigen-specific or non-specific
interventions have shown some benefit in modulation of the
autoimmune process and in preventing the loss of insulin
secretion in the short term after diagnosis of T1D. Even with
all the enthusiasm and progress in the field, unfortunately a
single long-term effective therapy has not been identified.
There are still limitations to current strategies, including a lack
of suitable markers to predict and monitor the success of
interventions, uncertainty about the long-term adverse effects
or the duration of treatment effect and the feasibility of resto-
ration of B-cell mass. Moreover, we should remember that
T1D is a heterogeneous disease with an age at onset spanning
from childhood to adult age, sometimes with clinical features
of Type 2 diabetes such as LADA [71]. Therefore, interventions
to protect or regenerate B-cell function whilst managing
hyperglycaemia may vary depending on the age of onset of the
disease and the extent of pancreatic B-cell damage. It is likely
that in most cases a rationally designed combination approach
with immunotherapeutic methods which target suppression of
pathogenic autoreactivity and induction of immunoregulatory
pathways coupled with islet regeneration will prove to be most
effective. Ideally, the interventions would be specific for T1D,
free of adverse effects and effective prior to disease onset, with
long-term and clinically meaningful improvements over
standard therapies. The success of these approaches will
eventually be evaluated by their impact on glycaemic control
as this is the definitive determinant of long-term outcome of
the disease.
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